Multi-gene ctDNA profiling effectively matches patients with advanced cancer to targeted therapies
In France, a nationwide programme aims to broaden access to the technology based on the positive results collected so far
From precision oncology to molecular prevention – a new role for our profession?
As rapid scientific and technological progress raises hopes of more cancers being intercepted at the earliest stages in the future, ESMO delves deeper into prevention to ensure education and guidance for medical oncologists in this moving field
Cancer in old patients: geriatric assessment and management plays a crucial role to provide personalised care
First recommendations are released from the ESMO/SIOG Cancer in the Elderly Working Group
First gene engineered T-cell therapy for solid tumours confirmed to be a promising tool
The positive results of the SPEARHEAD-1 trial which showed durable responses of afamitresgene autoleucel in unresectable or metastatic synovial sarcoma granted FDA accelerated approval
First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors
Eftilagimod alpha plus pembrolizumab shows promise in HNSCC with negative PD-1 expression
In the Cohort B of the TACTI-003 study, the combination therapy led to clinically meaningful response rates in patients with recurrent or metastatic disease
How to interpret genomic testing results? ESMO recommendations to make reports easy to read
The aim is to harmonise results between different laboratories and facilitate clinical decision-making for physicians
Oncologists do not feel well-prepared to address the health needs of LGBTQ cancer patients
In an ESMO-SIOPE survey, only 10% of respondents report they received adequate education in medical school about how to tailor cancer care to this population
Growing evidence supports the use of ctDNA as a biomarker in colon cancer
Data from clinical trials show the value of liquid biopsy in treatment decision-making and prognostication
Liver transplantation plus chemotherapy prolongs survival in patients with definitively unresectable colorectal liver metastases
In the TRANSMET trial, a 5-year overall survival benefit was observed in a highly selected patient population